黑料网

Research Article

The Development of an At-Risk Biosensor for Cardiovascular Disease

Sandra Ivonne Gonzalez¹ and Jeffrey T. La Belle^2*

¹Department of Biomedical Engineering, College of Engineering, The University of Arizona, Tucson, AZ 85721, USA

²Harrington Biomedical Engineering Program, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85287, USA

*Corresponding Author:

Jeffrey T. La Belle
E-mail: jeffrey.labelle@asu.edu

Received date: 27 July 2012; Revised date: 29 September 2012; Accepted date: 13 October 2012

Cardiovascular disease (CVD) is a leading cause of death worldwide. Several biomarkers have been found useful in diagnosis and management of CVD, so there is an enormous potential utility for a point-of-care biosensor capable of measuring the entire panel of CVD biomarkers on demand. This paper presents one potential component of such a biosensor, in the form of an electrochemical impedance spectroscopy (EIS)-based measurement method for one such CVD biomarker, neutrophil gelatinaseassociated lipocalin (NGAL). In this study, an antibodyfunctionalized gold disk electrode is shown to detect NGAL in blood diluted to 10% concentration, with a slope of 5.6824 ohms/LOG (ng/mL) and an R2 of 0.97 (n = 3) at 1.758 kHz. These results show the feasibility of an EISbased point-of-care biosensor for CVD markers. Future work will include expanding the method demonstrated here to cover other CVD biomarkers and integrating multiple markers into a single sensor device.

Keywords